ArticleTherapeutic advances in neurological disorders2010
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.
Article in Therapeutic advances in neurological disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080270 (Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis), which is not on this map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review.Dysphagia · 2016Pooled it
- Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Middle-range scores from the patient determined disease steps scale reflect varying levels of walking dysfunction in multiple sclerosis.BMC neurology · 2024Trial
- Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Trial
- Trial
- Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.Multiple sclerosis (Houndmills, Basingstoke, England) · 2017Trial
- Trial
- A randomised controlled trial of an exercise plus behaviour change intervention in people with multiple sclerosis: the step it up study protocol.BMC neurology · 2014Trial
- Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.Multiple sclerosis (Houndmills, Basingstoke, England) · 2014Trial
- Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.PloS one · 2013Trial
- Ventricular-vascular coupling at rest and immediately following maximal exercise in adults with and without multiple sclerosis.Physiological reports · 2026Article
- Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026Review
- Eyes closed single-leg stance test detects subtle sensorimotor decline in early multiple sclerosis.Scientific reports · 2026Article
- Association of angiotensin converting enzyme type 2 serum level and gene polymorphisms with multiple sclerosis.Scientific reports · 2026Article
- From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.Annals of neurology · 2026Article
- Current status and future prospects of brain-computer interfaces in the field of neurological disease rehabilitation.Frontiers in rehabilitation sciences · 2026Review
- Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.Neurology · 2025Article
- Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.Neurology · 2025Observational
- Prediction of future aging-related slow gait and its determinants with deep learning and logistic regression.PloS one · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease with both clinical and pathological heterogeneity. The complexity of the MS population has offered challenges to the measurement of MS disease progression in therapeutic trials. The current standard clinical outcome measures are relapse rate, Expanded Disability Severity Scale (EDSS), and the MS Functional Composite (MSFC). These measures each have strengths and some weakness. Two additional measures, the six-minute walk and accelerometry, show promise in augmenting current measures. MS therapeutics is a quickly advancing field which requires sensitive clinical outcome measures that can detect small changes in disability that reliably reflect long-term changes in sustained disease progression in a complex population. A single clinical outcome measure of sustained disease progression may remain elusive. Rather, an integration of current and new outcome measures may be most appropriate and utilization of different measures depending on the MS population and stage of the disease may be preferred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.